Overview
Accendra Health provides in-home healthcare products and services nationwide, connecting patients, providers, and insurers to support care at home. Its offerings come through patient-direct brands Apria and Byram Healthcare, which supply home medical equipment, diabetes supplies, and respiratory care, coordinated through logistics and care networks so patients can receive services at home. The company differentiates itself by focusing entirely on home healthcare, leveraging its established brands and an integrated network that links patients with clinicians and payers. Its goal is to make home-based care accessible, efficient, and effective, improving health outcomes outside traditional hospital settings.
Work here?Claim your company
Simplify's take
What believers are saying
- November 2, 2026 extended the $150 million receivables sale program through 2029.
- S&P expects 2027-2028 revenue growth from sleep therapy, wound, ostomy, and urology.
- Accendra's direct competitive-bidding exposure is only 6%-7% of revenue, limiting 2028 damage.
What critics are saying
- Third-quarter 2026 revenue fell to $601.8 million, with adjusted EBITDA down to $47.8 million.
- S&P said a large commercial payor contract cut 2026 sales about 6%.
- Apria's breach litigation and state AG scrutiny keep multi-year legal exposure alive.
What makes Accendra Health unique
- Apria and Byram give Accendra Health national home-based care reach after 2025 divestiture.
- January 2, 2026 NYSE trading under ACH cleaned up the parent-company story.
- November 5, 2026 value-creation plan signals management is rebuilding around collections and profitability.
Help us improve and share your feedback! Did you find this helpful?